Business Context and Reporting Period
Cytosorbents Corp (Nevada) filed a Form 8-K on March 7, 2014, reporting the entry into a material definitive agreement for a public offering. The transaction closed on March 12, 2014.
Key Financial Metrics
- Gross Proceeds: $10,200,000 from the sale of 40,800,000 units.
- Net Proceeds: Approximately $9.45 million.
- Unit Composition: One share of Common Stock and one warrant to purchase 0.50 shares.
- Warrant Terms: Exercise price of $0.3125 per share; 5-year term; exercisable for cash only if an effective registration statement exists.
- Placement Agent Fees: 6% of gross proceeds in cash plus a warrant to purchase 1,224,000 shares at $0.30 per share.
- Expense Reimbursement: Up to 2% of gross proceeds for out-of-pocket expenses.
Material Changes
The filing details a significant capital raise event. The company increased its registered securities amount to $16,575,000 (assuming full cash exercise of warrants) through an additional registration statement. The filing does not provide comparative financial data (revenue, profit, or margins) as this is a current report regarding a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Use of Proceeds
Use of Proceeds: Funds will be allocated to building sales and marketing infrastructure, conducting clinical studies, working capital, and general corporate purposes.
Contingencies: Warrants are only exercisable for cash if an effective registration statement is in place at the time of exercise. The Placement Agent holds a right of first refusal for 12 months on subsequent offerings.
Risks: The filing notes that the Placement Agent is not required to sell a minimum amount of securities, relying instead on "reasonable best efforts."
Investor Verification Checklist
- Verify the final closing date of March 12, 2014, and confirm receipt of net proceeds.
- Review the effective registration statements (File No. 333-193053 and 333-194394) to confirm the status of warrant exercisability.
- Assess the dilution impact of 40,800,000 new shares plus potential conversion of 20,400,000 warrant shares and 1,224,000 placement agent warrant shares.
- Confirm the specific allocation of the $9.45 million net proceeds to clinical studies and marketing as stated.